Exchange Component definition

Exchange Component means any Goods sold by Absolute Aircraft Parts to the Customer in terms of an Exchange Sale;
Sample 1Sample 2
Exchange Component means a Component that is provided as part of the Exchange Program by AVEOS.
Sample 1Sample 2
Exchange Component means a Component, APU or Landing Gear provided to Customer by Supplier by way of Advance Exchange in return for Customer’s Unserviceable Component in accordance with the provisions of this Schedule.
Sample 1

Examples of Exchange Component in a sentence

  • Upon receipt of the Exchange Component, Customer has thirty (30) calendar days to tender the defective component to the return carrier for shipment to Grass Valley’s service center.

  • Prior to dispatch of an Exchange Component, a Grass Valley technical phone support specialist, contacted by Customer, must determine a defective component is the cause of the malfunction and that it must be repaired or replaced.

  • All defective components replaced by Grass Valley with an Exchange Component become the property of Grass Valley.

  • Grass Valley shall pay shipping charges for the Exchange Component to Customer.

  • Grass Valley shall bear the risk of loss or damage while the Exchange Component is in transit to Customer from the service center.

  • An Exchange Component may be an alternate component to replace the defective component, and shall meet or exceed the specifications of the replaced component.

  • Grass Valley will ship an Exchange Component to Customer within the applicable time specified in the Table set forth in Section 5 for all Critical Failures (as defined below) and within a commercially reasonable time for all other failures provided an Exchange Component is needed to solve the reported problem.

  • Grass Valley will ship an Exchange Component to Customer within the time specified in the Table set forth in Section 10.4 for all Critical Failures and within a commercially reasonable time for all other failures provided an Exchange Component is needed to solve the reported problem.

  • In the case of an Exchange Component AVEOS additionally shall make available, upon VOLARIS` request, full traceability of such Exchange Component.

  • Grass Valley will ship an Exchange Component to Customer within the applicable time specified in the Table set forth in Section 5 for all Critical Failures (as defined above in Section 5) and within a commercially reasonable time for all other failures provided an Exchange Component is needed to solve the reported problem.

Related to Exchange Component

  • Exchange Contract means a contract for a Commodity approved by SFC and HKFE for trading on one of the markets from time to time established and operated by HKFE which may result in a Futures Contract and/or an Option Contract;

  • Securities and Exchange Commission means the United States Securities and Exchange Commission.

  • Distribution Statement has the meaning set forth in Section 5.02(c) of the Trust Agreement.

  • Change Control means the process set out in Section 2.6.

  • Exchange Consideration shall have the meaning set forth in Section 11(b)(i).

  • Pivotal Trial means a clinical study in humans of the efficacy and safety of a Licensed Product that is prospectively designed to demonstrate with statistical significance that such product is effective and safe for use in a particular indication in a manner sufficient to file for Marketing Approval of such product and would satisfy the requirements of 21 CFR 312.21(c), or a similar clinical study prescribed by the Regulatory Authorities in a country other than the United States.

  • Dental Treatment means a treatment related to teeth or structures supporting teeth including examinations, fillings (where appropriate), crowns, extractions and surgery.

  • Unproven/ Experimental treatment means the treatment including drug experimental therapy which is not based on established medical practice in India.

  • Additional SDU Study means a deliverability study that a Developer may elect to pursue as that term is defined in OATT Section 25 (OATT Attachment S). For purposes of Section 23.4.5 of this Attachment H, “Affiliated Entity” shall mean, with respect to a person or Entity:

  • IND means (i) an investigational new drug application filed with the FDA for authorization to commence clinical studies and its equivalent in other countries or regulatory jurisdictions and (ii) all supplements and amendments that may be filed with respect to the foregoing.

  • Less restrictive alternative treatment means a program of

  • Qualified residential treatment program means a program that (i) provides 24-hour residential

  • Change Control Note (“CCN”) means the agreed Schedule 3 annexed to the Contract containing details of agreed Variations to the Contract.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • New Registration Statement has the meaning set forth in Section 2(a).

  • Change Control Process has the meaning set forth in Section 2(B) of the Agreement.

  • Regulatory Capital Treatment Event means the good faith determination by the Corporation that, as a result of (i) any amendment to, or change in, the laws or regulations of the United States or any political subdivision of or in the United States that is enacted or becomes effective after the initial issuance of any share of Series F Preferred Stock, (ii) any proposed change in those laws or regulations that is announced after the initial issuance of any share of Series F Preferred Stock, or (iii) any official administrative decision or judicial decision or administrative action or other official pronouncement interpreting or applying those laws or regulations that is announced after the initial issuance of any share of Series F Preferred Stock, there is more than an insubstantial risk that the Corporation will not be entitled to treat the full liquidation value of the shares of Series F Preferred Stock then outstanding as “tier 1 capital” (or its equivalent) for purposes of the capital adequacy guidelines of the Board of Governors of the Federal Reserve System, Regulation Y, 12 CFR 225 (or, as and if applicable, the capital adequacy guidelines or regulations of any successor Appropriate Federal Banking Agency), as then in effect and applicable, for as long as any share of Series F Preferred Stock is outstanding.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Clinical Studies means Xxxxx 0, Xxxxx 0, Xxxxx 0, Xxxxx 3, and such other tests and studies in human subjects that are required by Applicable Law, or otherwise recommended by the Regulatory Authorities, to obtain or maintain Regulatory Approvals for a Licensed Product for one (1) or more indications, including tests or studies that are intended to expand the Product Labeling for such Licensed Product with respect to such indication.

  • Exchange Area means an area, defined by the Commission, for which a distinct local rate schedule is in effect.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Registration Application means an application for registration of this Agreement as a planning agreement on the title of the Land pursuant to Section 7.6 of the Act in a form approved by the Registrar General;

  • Multiple Exchange Carriers Ordering and Design or “MECOD” means the Guidelines for Access Services - Industry Support Interface, a document developed by the Ordering/Provisioning Committee of the OBF, which functions under the auspices of the Carrier Liaison Committee of ATIS. The MECOD document, published by ATIS as ATIS/OBF- MECAB-Issue 3, February 1993, establishes methods for processing orders for access service which is to be provided to an IXC by two (2) or more telecommunications providers.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Opioid treatment program means a detoxification or maintenance treatment program which is required to report patient identifying information to the central registry and which is located in the state.

  • Active treatment means the implementation of an individualized care plan developed under and supervised by a physician and other qualified mental health professionals that prescribes specific therapies and activities.